NCT04047680View on ClinicalTrials.gov

eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs

CompletedOBSERVATIONAL
Enrollment

441

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

June 30, 2019

Conditions
Hepatitis CRenal DiseaseViral Hepatitis C
Interventions
DRUG

Sofosbuvir / Velpatasvir Oral Tablet

Sofosbuvir/velpatasvir for 12 weeks

DRUG

Sofosbuvir and Ledipasvir

Sofosbuvir and ledipasvir for 12 weeks

DRUG

Sofosbuvir Tablets

Sofosbuvir plus ribavirin (RBV) or daclatasvir (DCV) for 12 weeks

DRUG

Ombitasvir/paritaprevir/ritonavir

Ombitasvir/paritaprevir/ritonavir for 12 weeks

DRUG

Elbasvir / Grazoprevir Oral Tablet

Elbasvir/grazoprevir for 12 weeks

DRUG

Glecaprevir and Pibrentasvir

Glecaprevir/pibrentasvir for 12 weeks

Trial Locations (2)

10002

National Taiwan University Hospital, Yun-Lin Branch, Douliu

National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER

NCT04047680 - eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs | Biotech Hunter | Biotech Hunter